sex hormone binding globulinGenealiases: ABP · SBP · TEBG
Q-omics provides the consensus-scored SHBG profile across patient tissues and cancer cell-line models. SHBG expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SHBG is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SHBG protein abundance shows 23,336 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where SHBG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHBG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHBG survival associations across molecular data types. SHBG RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHBG RNA expression–survival associations across cancer types. High SHBG expression shows unfavorable associations in KICH, KIRC, COAD and CHOL, but favorable associations in BRCA and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for SHBG RNA expression.
This table summarizes SHBG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SHBG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHBG shows lower tumor expression in KIRC, KICH, THCA, KIRP, LUAD and LIHC. The KIRC box plot shows higher SHBG RNA expression in normal versus tumor tissue (log2 FC = −1.036, t-test p < 0.001).
This table shows molecular features associated with SHBG in patient tissues and cancer cell lines. In patient samples, SHBG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHBG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and KIDNEY.
